Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 14/20 | 0.71 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GRK5 | P34947 | 1/20 | 0.42 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17716273 | 0.82 | ELANE (0.89) | ELANEPGRNPSR1 | |
| SCHEMBL828772 | 0.80 | ELANE (0.53) | ELANELMNANPSR1GRK5TYRO3 | |
| SCHEMBL2047107 | 0.79 | PGR (0.48) | ELANEPGRLMNAGRK5TYRO3 | |
| SCHEMBL17716645 | 0.76 | ALDH1A1 (0.46) | ELANEPGRLMNAGRK5TYRO3 | |
| SCHEMBL17716644 | 0.76 | ELANE (0.46) | ELANE | |
| SCHEMBL28312902 | 0.76 | ELANE (0.71) | ELANEPGRNPSR1 | |
| SCHEMBL267675 | 0.76 | ELANE (0.56) | ELANELMNANPSR1 | |
| SCHEMBL10952562 | 0.75 | ELANE (1.00) | ELANELMNANPSR1 | |
| SCHEMBL2050104 | 0.74 | ELANE (0.43) | ELANEPGRLMNAGRK5TYRO3 | |
| SCHEMBL2050106 | 0.74 | ELANE (0.43) | ELANEPGRLMNAGRK5TYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 920 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | claimed |
| WO-2011132171-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | WO | claimed |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | US | claimed |
| WO-2010054286-A2 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | claimed |
| CN-101484152-A | Therapeutic combination for painful medical conditions | SANOL ARZNEI SCHWARZ GMBH (DE) | 2009-07-15 | — | — | CN | claimed |
| EP-2026788-A1 | THERAPEUTIC COMBINATION FOR PAINFUL MEDICAL CONDITIONS | SCHWARZ PHARMA AG (DE) | 2009-02-25 | — | — | EP | claimed |
| WO-2007141018-A1 | THERAPEUTIC COMBINATION FOR PAINFUL MEDICAL CONDITIONS | SCHWARZ PHARMA AG (DE) | 2007-12-13 | — | — | WO | claimed |
| US-20070043120-A1 | Therapeutic combination for painful medical conditions | UCB PHARMA GMBH (DE) | 2007-02-22 | — | — | US | claimed |
| US-20070042969-A1 | Combination therapy for pain in painful diabetic neuropathy | SRZ PROPERTIES, INC. (US) | 2007-02-22 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-20260007660-A1 | TREATMENT AND PREVENTION OF SLEEP DISORDERS | PURDUE PHARMA L.P. (US) | 2026-01-08 | — | — | US | disclosed |
| US-12370191-B2 | Treatment and prevention of sleep disorders | PURDUE PHARMA L.P. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250134886-A1 | SLEEP DISORDER TREATMENT AND PREVENTION | PURDUE PHARMA L.P. (US) | 2025-05-01 | — | — | US | disclosed |
| EP-0010992-B1 | PROCESS FOR THE PREPARATION OF 1-HYDROXYLATED VITAMIN D COMPOUNDS | RESEARCH INSTITUTE FOR MEDICINE AND CHEMISTRY INC. (US) | 1982-05-05 | — | — | EP | disclosed |
| US-4263215-A | OXIDIZING TRANS VITAMIN D3 OR A DERIVATIVE WITH A SELENITE ESTER; EFFICIENCY | RESEARCH INSTITUTE FOR MEDICINE AND CHEMISTRY, INC. (US) | 1981-04-21 | — | — | US | disclosed |
| EP-0010992-A1 | Process for the preparation of 1-hydroxylated vitamin D compounds | RESEARCH INSTITUTE FOR MEDICINE AND CHEMISTRY INC. (US) | 1980-05-14 | — | — | EP | disclosed |
| US-4159326-A | Hydrogenation process for the preparation of 5,6 cis- and 5,6-trans-10,19-dihydro-vitamin D compounds using transistion metal catalysts | RESEARCH INSTITUTE FOR MEDICINE & CHEMISTRY, INC. (US) | 1979-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042969-A1 | Combination therapy for pain in painful diabetic neuropathy | GRIN2B, GRIN2A, GRIN3A | ELANE 2363/4885PGR 3944/4885LMNA 4139/4885 |
| US-20260007660-A1 | TREATMENT AND PREVENTION OF SLEEP DISORDERS | CRY1, PER2, SLC6A1 | ELANE 2258/4885PGR 3620/4885LMNA 2057/4885 |
| US-12370191-B2 | Treatment and prevention of sleep disorders | HCRTR1, HCRTR2, MTNR1A | ELANE 1791/4885PGR 2178/4885LMNA 1262/4885 |
| US-20250134886-A1 | SLEEP DISORDER TREATMENT AND PREVENTION | HCRTR2, HCRTR1, CRY1 | ELANE 2718/4885PGR 1708/4885LMNA 831/4885 |
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | MC1R, TYR, MITF | ELANE 1207/4885PGR 106/4885LMNA 2644/4885 |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | NOS2, NOS1, NOS3 | ELANE 900/4885PGR 1765/4885LMNA 3648/4885 |
| US-20070043120-A1 | Therapeutic combination for painful medical conditions | PDE1B, CA2, CACNA1S | ELANE 387/4885PGR 4077/4885LMNA 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.